Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Demographic, clinical and patient-reported characteristics of patients on ocrelizumab versus other disease-modifying therapies in the Corrona Multiple Sclerosis Registry
Multiple Sclerosis
P9 - Poster Session 9 (12:00 PM-1:00 PM)
9-014
Describe characteristics of patients with multiple sclerosis (MS) enrolled in the Corrona MS Registry who received ocrelizumab or other disease-modifying therapies (DMTs).
Ocrelizumab was approved in 2017 for treatment of relapsing forms of MS and primary progressive MS (PPMS). To date, little is known about real-world use of ocrelizumab.
Corrona is a prospective, noninterventional, observational registry in the United States. Physicians from 11 US private and academic sites enrolled patients with MS aged ≥18 years; the registry currently includes 784 patients on therapy, of whom 37% are being treated with ocrelizumab. This study includes only patients treated for ≤24 months with ocrelizumab or other US Food and Drug Administration (FDA) approved DMTs at registry enrollment to allow for comparability, given ocrelizumab’s 2017 FDA approval. Demographics and clinical characteristics were described separately for patients treated with ocrelizumab and other DMTs.
Of 326 patients included at enrollment, 71% (n=233) were treated with ocrelizumab and 93 with other DMTs (46% orals, 44% intravenous, 10% injectables). Compared with other DMTs, ocrelizumab-treated patients were older (mean age, 51 vs 46 years), had longer mean disease duration (13 vs 9 years) and more frequently had PPMS (10% vs 1%). Ocrelizumab was used third line or later in 64% of patients, with patients most commonly switching from another intravenous DMT (27%); other DMTs were most often used first or second line (64%). Physicians indicated disability as the reason for starting current therapy more often with ocrelizumab than other DMTs (25% vs 19%).
In the 2 years following ocrelizumab approval, patients in the Corrona registry treated with ocrelizumab were older, more frequently had PPMS and more often received treatment third line compared with those on other DMTs. As the registry matures, future research will evaluate real-world outcomes in patients treated with ocrelizumab.
Authors/Disclosures
Daniel Kantor, MD, FÂ鶹´«Ã½Ó³»­ (Medical Partnership 4 MS+)
PRESENTER 		Dr. Kantor has received personal compensation for serving as an employee of Gateway Institute for Brain Research. Dr. Kantor has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Kantor has a non-compensated relationship as a HAP with MSFous (MSF) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Kantor has a non-compensated relationship as a Medical Board with MS Views & News that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Natalie J. Engmann, PhD (Genentech, Inc) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Aaron E. Miller, MD, FÂ鶹´«Ã½Ó³»­ (Mt Sinai School Of Med) Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Accordant Health Services (Caremark). Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Corevitas (formerly known as Corrona). Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MAPI=Pharma. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Viatris (Mylan). Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen (Horizon Therapeutics). Dr. Miller has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Sterne Kessler. Dr. Miller has received publishing royalties from a publication relating to health care.